

May 13, 2014



OncoSec Medical To Present At The Third Annual Marcum MicroCap Conference

SAN DIEGO, May 13, 2014 /PRNewswire/ -- OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, announced today that it will be a featured presenter at the [3rd Annual Marcum MicroCap Conference](#) on Thursday, May 29, 2014 in New York City at the Grand Hyatt Hotel.

The Company's presentation by Punit Dhillon, President and CEO, is scheduled to begin at 1:30 p.m. ET and will be available via a live webcast. To access the webcast, go to <http://wsw.com/webcast/marcum2/oncs>

The annual Marcum MicroCap Conference is a signature showcase for superior quality, under-followed public companies with less than \$500 million in market capitalization.

For more information or to register, please visit the conference website at <http://www.marcumllp.com/microcap> or download the free official conference app for the iPhone, iPad, or for Android mobile devices in [Apple's App Store](#) and the [Google Play Market](#).

About OncoSec Medical Inc.

OncoSec Medical Inc. is a biopharmaceutical company developing its ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical's core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of IL-12 and other DNA-based immune-modulating agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response while minimizing the systemic toxicities associated with other treatments. OncoSec's clinical programs currently include three Phase 2 trials targeting metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma (<http://clinicaltrials.gov/ct2/results?term=oncosec&Search=Search>). As the company continues to evaluate ImmunoPulse in these indications, it is also investigating additional indications and combination-based therapeutic approaches. For more information, please visit www.oncosec.com.

About Marcum LLP

Marcum LLP is one of the largest independent public accounting and advisory services firms in the United States. Ranked #15 nationally, Marcum LLP offers the resources of 1,300 professionals, including over 160 partners, in 23 offices throughout the U.S., Grand Cayman and China. Headquartered in New York City, the Firm's presence runs deep, with full-service offices strategically located in major business markets. Marcum is a member of the Marcum Group, an organization providing a comprehensive range of professional services spanning accounting and advisory, technology solutions, wealth management, and executive and

professional recruiting. The Marcum Group companies include [Marcum LLP](#); [Marcum Technology LLC](#); [Marcum Search LLC](#); [Marcum Financial Services LLC](#); [Marcum Bernstein & Pinchuk LLP](#); [MarcumBuchanan Associates LLC](#); and [Marcum Cronus Partners LLC](#). For more information, visit www.marcumllp.com.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements." Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

News Release

Investor Relations:

OncoSec Medical

Veronica Vallejo, CFO

855-662-6732

investors@oncosec.com

SOURCE OncoSec Medical Inc.